Month: April 2015
Could CRISPR be the Magic Bullet?
The patent fight over the next generation genome targeting tool – the CRISPR genes
CRISPR germline editing reverberates through biotech community
The organizers of a recent meeting in Napa, California, to consider the broad societal implications of clustered, regularly interspaced, short palindromic repeats (CRISPR) genome editing have succeeded in their primary goal of stimulating public debate on the ethical issues raised by the technology. Although the...
Read More
7 Gene Editing Companies Investors Should Watch
HOW WAS IT DONE?
The team tried to tweak the gene responsible for ß-thalassaemia, a potentially deadly blood disorder, using a germ line editing technique known as CRISPR/Cas9. CRISPR technology precisely changes target parts of genetic code. Unlike other gene-silencing tools, the CRISPR system targets the genome’s source material...
Read More
Chinese scientists just admitted to tweaking the genes of human embryos for the first time in history
CRISPR Digest #5
Cellectis signed CRISPR/Cas9 licensing deal with University of Minnesota
Cellectis Plant Sciences recently announced it has signed an exclusive licensing agreement with the University of Minnesota, granting the firm worldwide rights to patents covering the use of CRISPR/Cas9 technology in plants. The technology, developed for genome engineering in plants by University of Minnesota Professor...
Read More